Cytotoxic Effects of 3,4-Catechol-PV (One Major MDPV Metabolite) on Human Dopaminergic SH-SY5Y Cells

[1]  M. Olive,et al.  Neurocognitive dysfunction following repeated binge-like self-administration of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) , 2018, Neuropharmacology.

[2]  S. Perrine,et al.  Repeated exposure to 3,4-methylenedioxypyrovalerone and cocaine produces locomotor sensitization with minimal effects on brain monoamines , 2017, Neuropharmacology.

[3]  S. Krähenbühl,et al.  Mechanisms of hepatocellular toxicity associated with new psychoactive synthetic cathinones. , 2017, Toxicology.

[4]  J. Duarte,et al.  Methylone and MDPV activate autophagy in human dopaminergic SH-SY5Y cells: a new insight into the context of β-keto amphetamines-related neurotoxicity , 2017, Archives of Toxicology.

[5]  M. Grapp,et al.  Toxicological investigation of forensic cases related to the designer drug 3,4-methylenedioxypyrovalerone (MDPV): Detection, quantification and studies on human metabolism by GC-MS. , 2017, Forensic science international.

[6]  E. Fernandes,et al.  Neurotoxicity of β-Keto Amphetamines: Deathly Mechanisms Elicited by Methylone and MDPV in Human Dopaminergic SH-SY5Y Cells. , 2017, ACS chemical neuroscience.

[7]  Mariana Angoa-Pérez,et al.  Neurotoxicology of Synthetic Cathinone Analogs. , 2016, Current topics in behavioral neurosciences.

[8]  Kurt R. Lehner,et al.  Neuropharmacology of 3,4-Methylenedioxypyrovalerone (MDPV), Its Metabolites, and Related Analogs. , 2017, Current topics in behavioral neurosciences.

[9]  Ana Margarida Araújo,et al.  Editor's Highlight: Characterization of Hepatotoxicity Mechanisms Triggered by Designer Cathinone Drugs (β-Keto Amphetamines). , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[10]  M. Paule,et al.  3,4-methylenedioxypyrovalerone (MDPV) Induces Cytotoxic Effects on Human Dopaminergic SH-SY5Y Cells , 2016 .

[11]  M. Paule,et al.  Methamphetamine, 3,4-methylenedioxymethamphetamine (MDMA) and 3,4-methylenedioxypyrovalerone (MDPV) induce differential cytotoxic effects in bovine brain microvessel endothelial cells , 2016, Neuroscience Letters.

[12]  Marcia Constantinou,et al.  A fatal intoxication related to MDPV and pentedrone combined with antipsychotic and antidepressant substances in Cyprus. , 2016, Forensic science international.

[13]  J. Zawilska,et al.  Cytotoxic Activity of Pyrovalerone Derivatives, an Emerging Group of Psychostimulant Designer Cathinones , 2016, Neurotoxicity Research.

[14]  Kurt R. Lehner,et al.  Linear pharmacokinetics of 3,4‐methylenedioxypyrovalerone (MDPV) and its metabolites in the rat: relationship to pharmacodynamic effects , 2016, Addiction biology.

[15]  Ana Margarida Araújo,et al.  3,4-Methylenedioxypyrovalerone (MDPV): in vitro mechanisms of hepatotoxicity under normothermic and hyperthermic conditions , 2016, Archives of Toxicology.

[16]  Kurt R. Lehner,et al.  Reinforcing and neurochemical effects of the “bath salts” constituents 3,4-methylenedioxypyrovalerone (MDPV) and 3,4-methylenedioxy-N-methylcathinone (methylone) in male rats , 2016, Psychopharmacology.

[17]  E. Mervaala,et al.  Mitochondrial respiratory dysfunction due to the conversion of substituted cathinones to methylbenzamides in SH-SY5Y cells , 2015, Scientific Reports.

[18]  J. Camarasa,et al.  Concentrations of MDPV in rat striatum correlate with the psychostimulant effect , 2015, Journal of psychopharmacology.

[19]  C. Erratico,et al.  In vitro Phase I and Phase II metabolism of α-pyrrolidinovalerophenone (α-PVP), methylenedioxypyrovalerone (MDPV) and methedrone by human liver microsomes and human liver cytosol , 2015, Analytical and Bioanalytical Chemistry.

[20]  M. Liechti,et al.  Monoamine transporter and receptor interaction profiles of novel psychoactive substances: Para-halogenated amphetamines and pyrovalerone cathinones , 2015, European Neuropsychopharmacology.

[21]  Laurent Karila,et al.  Synthetic Cathinones: A New Public Health Problem , 2015, Current neuropharmacology.

[22]  E. Mervaala,et al.  Keto amphetamine toxicity-focus on the redox reactivity of the cathinone designer drug mephedrone. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[23]  A. Csillag,et al.  Apoptotic effects of the 'designer drug' methylenedioxypyrovalerone (MDPV) on the neonatal mouse brain. , 2014, Neurotoxicology.

[24]  E. Fernandes,et al.  The mixture of “ecstasy” and its metabolites is toxic to human SH-SY5Y differentiated cells at in vivo relevant concentrations , 2014, Archives of Toxicology.

[25]  K. Ferslew,et al.  Deaths Involving Methylenedioxypyrovalerone (MDPV) in Upper East Tennessee , 2013, Journal of forensic sciences.

[26]  Cassie L. Boggs,et al.  Methylenedioxypyrovalerone (“Bath Salts”),Related Death: Case Report and Review of the Literature , , 2013, Journal of forensic sciences.

[27]  J. Zawilska,et al.  Designer cathinones--an emerging class of novel recreational drugs. , 2013, Forensic science international.

[28]  Sharon Miksys,et al.  Cytochrome P450-mediated drug metabolism in the brain. , 2013, Journal of psychiatry & neuroscience : JPN.

[29]  Shaena Taylor,et al.  Postmortem tissue distribution of MDPV following lethal intoxication by "bath salts". , 2013, Journal of analytical toxicology.

[30]  Heather M. Antonides,et al.  Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results. , 2013, Journal of analytical toxicology.

[31]  Kurt R. Lehner,et al.  Powerful Cocaine-Like Actions of 3,4-Methylenedioxypyrovalerone (MDPV), a Principal Constituent of Psychoactive ‘Bath Salts’ Products , 2013, Neuropsychopharmacology.

[32]  M. Liechti,et al.  Pharmacological characterization of designer cathinones in vitro , 2013, British journal of pharmacology.

[33]  E. Fernandes,et al.  Neurotoxicity of "ecstasy" and its metabolites in human dopaminergic differentiated SH-SY5Y cells. , 2010, Toxicology letters.

[34]  R. Tyndale,et al.  Heinz Lehmann Award paper Cytochrome P 450 – mediated drug metabolism in the brain , 2013 .

[35]  C. Holstege,et al.  Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone. , 2012, Annals of emergency medicine.

[36]  G. Behonick,et al.  Analysis of first and second generation legal highs for synthetic cannabinoids and synthetic stimulants by ultra-performance liquid chromatography and time of flight mass spectrometry. , 2012, Journal of analytical toxicology.

[37]  Brittany L. Murray,et al.  Death Following Recreational Use of Designer Drug “Bath Salts” Containing 3,4-Methylenedioxypyrovalerone (MDPV) , 2012, Journal of Medical Toxicology.

[38]  R. Tyndale,et al.  Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. , 2011, Trends in pharmacological sciences.

[39]  P. Kriikku,et al.  New designer drug of abuse: 3,4-Methylenedioxypyrovalerone (MDPV). Findings from apprehended drivers in Finland. , 2011, Forensic science international.

[40]  Henry A Spiller,et al.  Clinical experience with and analytical confirmation of “bath salts” and “legal highs” (synthetic cathinones) in the United States , 2011, Clinical toxicology.

[41]  R. Tyndale,et al.  Cytochromes P450 in the brain: Emerging evidence for biological significance , 2011 .

[42]  M. Meyer,et al.  Studies on the metabolism of the α-pyrrolidinophenone designer drug methylenedioxy-pyrovalerone (MDPV) in rat and human urine and human liver microsomes using GC-MS and LC-high-resolution MS and its detectability in urine by GC-MS. , 2010, Journal of mass spectrometry : JMS.

[43]  X. de la Torre,et al.  Toxicological determination and in vitro metabolism of the designer drug methylenedioxypyrovalerone (MDPV) by gas chromatography/mass spectrometry and liquid chromatography/quadrupole time-of-flight mass spectrometry. , 2010, Rapid communications in mass spectrometry : RCM.

[44]  Marie-Anne Loriot,et al.  ABC transporters and cytochromes P450 in the human central nervous system: influence on brain pharmacokinetics and contribution to neurodegenerative disorders , 2010, Expert opinion on drug metabolism & toxicology.

[45]  R. Tyndale,et al.  Cytochrome P450 2D6 enzyme neuroprotects against 1‐methyl‐4‐phenylpyridinium toxicity in SH‐SY5Y neuronal cells , 2010, The European journal of neuroscience.

[46]  Donna D. Zhang,et al.  Nrf2 promotes neuronal cell differentiation. , 2009, Free radical biology & medicine.

[47]  K. Takata,et al.  Nicotinic receptor stimulation protects nigral dopaminergic neurons in rotenone‐induced Parkinson's disease models , 2009, Journal of neuroscience research.

[48]  Sabine Borwege,et al.  Terminally differentiated SH-SY5Y cells provide a model system for studying neuroprotective effects of dopamine agonists , 2009, Neurotoxicity Research.

[49]  L. Moens,et al.  The proteome of the human neuroblastoma cell line SH-SY5Y: an enlarged proteome. , 2008, Biochimica et biophysica acta.

[50]  J. Deschamps,et al.  1-(4-Methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (Pyrovalerone) analogues: a promising class of monoamine uptake inhibitors. , 2006, Journal of medicinal chemistry.

[51]  R. Hammond,et al.  Nestin Expression in Ganglioglioma , 2002, Experimental Neurology.

[52]  Beverley Rader Lugo,et al.  Clinical Experience , 2009 .

[53]  M. Macleod,et al.  Serum withdrawal causes apoptosis in SHSY 5Y cells , 2001, Brain Research.

[54]  R. Tyndale,et al.  Regional and cellular distribution of CYP2D subfamily members in rat brain , 2000, Xenobiotica; the fate of foreign compounds in biological systems.

[55]  A. Frankfurter,et al.  The expression and posttranslational modification of a neuron-specific beta-tubulin isotype during chick embryogenesis. , 1990, Cell motility and the cytoskeleton.

[56]  A. Frankfurter,et al.  The distribution of tau in the mammalian central nervous system , 1985, The Journal of cell biology.

[57]  L S Freedman,et al.  Multiple neurotransmitter synthesis by human neuroblastoma cell lines and clones. , 1978, Cancer research.